Recombinant CPSA Production in E. coli Using Modular Genes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge of isolating or synthesizing bacterial polysaccharides in large quantities is hindered by complex growth requirements, laborious isolation procedures, and difficulty in genetic manipulation of bacterial hosts, limiting their application in industries such as wound healing, pharmaceuticals, and cosmetics.
Innovation Solution
A method for producing polysaccharides in bacteria by expressing a plurality of coding sequences, including heterologous genes like pglF, wbpP, wcfR, and wcfS, which are operatively linked to a promoter, resulting in the production of capsular polysaccharide A (CPSA) in Escherichia coli, with optional inclusion of additional genes for enhanced synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional isolation methods are used to obtain bacterial polysaccharides, then the polysaccharide can be obtained from the bacterial host, but the process is laborious and yields are limited due to complex growth requirements
Solution Approach 1:
The patent applies the copying principle by transferring the polysaccharide biosynthesis pathway from the original bacterial host (Bacteroides fragilis) into a model organism (E. coli). The coding sequences for the polysaccharide synthesis enzymes are cloned into an E. coli expression system, allowing the polysaccharide to be produced using the well-established, simple E. coli biology rather than the complex B. fragilis system. This enables large-scale production while simplifying the manufacturing process.
Solution Approach 2:
The patent uses E. coli as an intermediary host to produce the polysaccharide. E. coli serves as a mediator between the polysaccharide biosynthesis pathway and the desired product, leveraging E. coli's ease of genetic manipulation and robust growth characteristics to produce the polysaccharide at scale, while the actual polysaccharide structure remains that of the original B. fragilis capsule.
2Productivity
If heterologous genes are expressed in E. coli to produce polysaccharide, then production efficiency is improved, but genetic manipulation complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the polysaccharide biosynthesis pathway into discrete coding sequences (pglF, wbpP, wcfR, wcfS, and optional genes). Each gene can be independently cloned and expressed in E. coli, allowing modular assembly of the pathway. This segmentation enables systematic optimization of each enzyme's expression and facilitates easier genetic manipulation compared to manipulating the entire pathway in the original host.
Data Source
AI summary
Provided are methods for producing polysaccharides in bacteria by expressing in a bacterium one or more coding sequences selected from the group consisting of a pglF dehydrogenase coding sequence, a wbpP UDP-N-acetyl-d-glucosamine C4 epimerase coding sequence, a wcfR aminotransferase coding sequence, and a wcfS phospho-glycosyltransferase coding sequence, a wcfQ glycosyltransferase coding sequence, a wcfO pyruvyltransferase coding sequence, a wcfP glycosyltransferase coding sequence, a wcfM UDP-galactopyranose mutase coding sequence, a wcfN glycosyltransferase coding sequence, a wza polysaccharide export protein coding sequence, a wzx fippase coding sequence, a wzy polymerase coding sequence, and a wzz coding sequence, wherein at least one of the coding sequences is heterologous to the bacterium. Also provided are expression cassettes with one or more of the disclosed coding sequences, recombinant bacteria that harbor one or more of the expression cassettes, and methods for producing immunogenic compositions using the polysaccharides produced by the recombinant bacteria.